Last checked at 6 Jul 2010 11:53
| For immediate release | 6 July 2010 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Exercise of Options and Director's Dealings
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that the Company was notified today that on 6 July 2010 Tony Booley, a Director of the Company, exercised options to acquire 79,416 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 9.25p per share, which were subsequently all sold on 6 July 2010 at 32.75 pence per share. Following these transactions, Mr Booley holds 6,810,723 Ordinary Shares in the Company, representing approximately 2.9% of the enlarged issued share capital.
Application has been made for the 79,416 Ordinary Shares to be admitted to AIM, with trading expected to commence on 12 July 2010 ("Admission"). Upon Admission, the new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.
After Admission, Alliance will have 232,494,038 Ordinary Shares in issue.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive Officer |
|
| Richard Wright, Finance Director |
|
| www.alliancepharma.co.uk |
|
Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Stasa Filiplic |
|
|
|
|
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Brent Nabbs |
|
| Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.